Harbour Biomed Regains Global Rights to HBM7008

On August 9, 2024, the company announced that it had successfully won back global development and commercialization rights to HBM7008 from Cullinan Oncology. This turning point marks the return of Cullinan Oncology's exclusive license to market HBM7008 in the United States, which was originally granted to Cullinan Oncology by Platinum Pharma in February 2023.

In accordance with the mutual termination agreement, Cullinan Oncology will formally withdraw from the partnership on the significant date of November 3, 2024. In particular, the transaction does not require any refund to Cullinan Oncology of any fees collected during the previous agreement, which undoubtedly provides a more solid financial foundation for the company's future growth.

In addition, the company holds valuable rights to conduct HBM7008 clinical trials in the European Union and Australia, and has access to all clinical data generated from these trials. This arrangement provides a solid foundation for further research and development of HBM7008 worldwide.

HBM7008, as a bisspecific antibody independently developed by Platinum Pharmaceutical, is unique in that it can simultaneously target B7-H4 and 4-1BB. At present, the drug is in the key stage of phase I clinical trials, and its indication is mainly focused on the treatment of solid tumors. The full recovery of the global development and commercialization interests of HBM7008 will undoubtedly provide a broader stage for Platinum Pharma to explore further the development potential of this drug and potential commercialization opportunities.

The company said it will continue to unswervably invest in the subsequent development and commercialization of HBM7008. They are committed to bringing new treatment options to patients through unremitting efforts and contributing their own strength to the cause of human health.